Abstract
Although cytomegalovirus (CMV) expresses proteins that interfere with antigen presentation by class I MHC molecules, CD8 + cytotoxic T cells (CTL) are indispensable for controlling infection and maintaining latency. Here, a cytokine flow cytometry assay that employs fibroblasts infected with a mutant strain of CMV (RV798), which is deleted of the four viral genes that are responsible for interfering with class I MHC presentation, was used to examine the frequency and specificity of the CD8 + CTL to CMV in immunocompetent CMV seropositive individuals. A large fraction of the CD8 + CTL response was found to be specific for viral antigens expressed during the immediate early and early phases of virus replication and presented by fibroblasts infected with RV798
but not wild type CMV. These results demonstrate that the inhibition of class I antigen presentation observed in CMV-infected cells in vitro is not sufficient to prevent the induction of a broad repertoire of CD8 + CTL after natural infection in vivo. Thus, reconstitution of T-cell immunity in immunodeficient patients by cell therapy or by vaccination may need to target multiple viral antigens to completely restore immunologic control of CMV.
Introduction
Human cytomegalovirus (CMV) infects one-half of the adult population and persists in the immunocompetent host as an asymptomatic latent infection. CMV causes severe disease in immunocompromised individuals including transplant recipients, individuals with human immunodeficiency virus infection, and congenitally infected infants [1] [2] [3] [4] . Studies in mice infected with murine CMV (MCMV), which shares biologic properties with human CMV, have identified a critical role for CD8 + T cell immunity in preventing lethal infection, limiting the viral load in latency, and reestablishing latency after reactivation [5] [6] [7] . A deficiency of functional CD8 + CMV-specific T cells also correlates with CMV disease in immunosuppressed patients 3, 8, 9 . These observations have led to efforts to restore protective responses by adoptive T-cell immunotherapy [10] [11] [12] [13] The design of protocols for reconstituting T-cell immunity in immunodeficient patients and the development of a vaccine to prevent congenital CMV infection would be facilitated by understanding the specificity of CD8 + T cells that contain CMV in the immunocompetent host. CD8 + T cells recognize peptides that are derived from intracellular proteins and displayed at the cell surface bound to class I MHC molecules.
The human CMV genome contains 230 kb of DNA and infected cells express more than 160 viral proteins that could provide antigenic peptides for CD8 + T cells 14 . However, the viral genome encodes four proteins (US2, US3, US6, and US11), that block the generation and/or export of class I MHC peptide complexes and induce a rapid decline in surface class I expression [15] [16] [17] [18] . Studies using fibroblasts permissively infected with wild type CMV or with recombinant viruses encoding individual CMV proteins as antigen presenting cells (APC) have identified only a small number of CMV antigens recognized
For personal use only. on . by guest www.bloodjournal.org From by CD8 + CTL. These include the virion proteins pp65 and pp150, which are presented to CTL shortly after viral entry without requiring de novo synthesis, and the major immediate early protein (IE-1), which is expressed at high levels in the first hours of infection [19] [20] [21] [22] [23] [24] [25] . Class I HLA tetramers complexed to pp65 or IE-1 peptides, or staining of intracellular cytokines induced in T cells after peptide stimulation, have been employed to quantitate CD8 + T cells specific in the blood of CMV seropositive individuals. A significant frequency (0.12 to >5%) of CD8 + T cells were specific for pp65 and IE-1, which led to the assumption they were immunodominant targets in humans, and to their inclusion in subunit vaccines 20, 21, [25] [26] [27] [28] [29] .
The recognition of only a few viral antigens by the CTL response to human CMV has been attributed to interference with class I antigen presentation mediated by the viral US proteins [15] [16] [17] [18] 24 . However, a variety of cell lineages may be infected with CMV and it is unknown if the inhibition of antigen presentation observed in fibroblasts in vitro is equivalent in all infected cells in vivo 30, 31 . Studies of the specificity of the CD8 + CTL response induced in mice by experimental inoculation with murine CMV identified CTL responses to CMV antigens that are not presented by cells infected with wild type CMV due to viral interference with class I antigen presentation [32] [33] [34] [35] . In humans, Elispot assays with synthetic peptides selected from 14 human CMV proteins identified in some donors a significant response to pp50 in addition to pp65 and IE-1, and a low frequency response to peptides from US2, US3, US6, US11, UL16 and UL18, which have not previously been identified as target antigens 36 . Therefore, it is conceivable that major CD8 + CTL responses specific for CMV antigens may be present in vivo but have gone undetected 
Methods

Viruses and Cell Lines
AD169 CMV was obtained from the American Type Culture Collection and the RV798 virus was generated as described 37 . Vaccinia recombinant viruses encoding the CMV major immediate early protein (Vac/IE), pp65 (Vac/pp65), and gB (Vac/gB) under the control of the p7.5 promoter were kindly provided by William Britt, University of Alabama. A vaccinia recombinant virus encoding pp150 (Vac/pp150) was constructed as described 22 .
Dermal fibroblast lines were generated from skin biopsies and propagated in Following transformation, LCL were propagated in RPMI, 10% FCS.
Cytokine Flow Cytometry Assay
Blood samples were obtained from CMV seropositive and CMV seronegative donors and used in CFC assays either directly or after separation into PBMC by FicollHypaque gradient centrifugation 38 . Briefly, 1 ml of whole blood or 1x10 6 PBMC was incubated at 37 0 C with 1 µg/ml anti-CD49d monoclonal antibody (mAb) (Becton Dickenson, San Jose, CA), 1 µg/ml anti-CD28 mAb (Becton Dickenson), and 5 x 10 5 autologous fibroblasts that were either mock-infected, infected with AD169 CMV for 24 hours, or infected with RV798 CMV for 48 hours at an MOI of 1. In some experiments,
For personal use only. on . by guest www.bloodjournal.org From peptides (5 µg/ml) corresponding to pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] , which binds to HLA A2, or pp65 [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] and pp65 [265] [266] [267] [268] [269] [270] [271] [272] [273] [274] , which bind to HLA B7, respectively, were used for stimulation by addition to 1 ml of whole blood or 1x10 6 γ-irradiated LCL in CTL media with 50 U/ml rhIL-2. After 14 days, a 30µl aliquot of cells from wells with visible growth were tested in a chromium release assay for recognition of autologous fibroblasts that were mock-infected or infected with RV798 for 48 hours. Clones that lysed RV798-infected fibroblasts (>10%) but not mock-infected fibroblasts (<1%) were expanded as described 12 .
Chromium Release Assay CD8 + T cell clones were assayed for cytotoxic activity in a chromium release assay (CRA) using 51 Cr-labeled fibroblasts infected with AD169 for 24 hours or infected with RV798 for 48 hours as target cells 19 . Target cells were plated in triplicate at 5x10 3 cells/well in 96 well round bottom plates, effector cells were added at various effector to target ratios, and after a 4-hour incubation, supernatant was harvested for gamma counting. In some experiments, the RNA polymerase inhibitor actinomycin D (Sigma) at 10 µg/ml, or ganciclovir (Sigma) at 10 µM were added to target cells 30 minutes before infection. The metabolic inhibitor was maintained in the media throughout all washes and the 4-hour CRA 19 . The ability of ganciclovir to block viral DNA replication was documented by the complete inhibition of virus production using standard plaque assays on human fibroblasts. The percent specific lysis was calculated using the standard formula. The HLA restricting allele of individual CTL clones was determined utilizing Clones were also tested for lysis of autologous LCL infected for 12 hours at an MOI of 10 with vaccinia recombinant viruses encoding individual CMV proteins, or pulsed with synthetic peptides synthesized by standard methods and corresponding to pp50 TLLNCAVTK and pp50 TVRSHCVSK that bind to HLA-A3, pp50 YEQHKITSY that binds to HLA-B44, pp28 LLIDPTSGL that binds to HLA-A2, pp28 ARVYEIKCR that binds to HLA-B27, and UL18 TENGSFVAGY that binds to HLA-B44 36 . A pp65 peptide panel consisting of 108
15-mer peptides that overlap by 5 amino acids was also used to pulse autologous EBV-LCL to screen for reactivity to pp65.
T cell receptor Vβ gene usage
RNA was isolated from T cell clones using RNeasy kit (Qiagen, Valencia, CA) and reverse-transcribed into cDNA using oligo (dT)15 primers (Invitrogen, Carlsbad, CA) and M-MLV reverse transcriptase (Invitrogen). The TCR Vβ gene usage of each T cell clone was determined using a TCR Vβ region specific multiplex RT-PCR as described 39
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Results
Quantitation of CD8 + CMV-specific T cells in blood by cytokine flow cytometry (CFC).
The frequency of T cells in the blood that are specific for peptides derived from pp65 or IE-1 has been measured by flow cytometry using class I HLA tetramers, or staining with a mAb that detects intracellular IFNγ following peptide stimulation with individual peptides or peptide pools 25, 26 . We wished to develop a method for quantitating CD8 + CMV-specific T cells in healthy CMV seropositive donors that were specific for any viral antigen displayed by the individual's class I alleles. Therefore, we evaluated whether CD8 + CMV-specific T cells in PBMC could be quantitated by CFC after stimulation with autologous fibroblasts infected with AD169 CMV or with the RV798 strain that contains a deletion of the US region 37 .
In initial experiments, fibroblasts were infected for various times with AD169 or induced IFNγ production in a larger fraction of CD8 + T cells, and the greatest response was elicited using fibroblasts infected for 48 hours (Figure 1c) . In these experiments, 0.23% to 2.96% (mean = 1.04%) of CD8 + T cells produced IFNγ after stimulation with AD169-infected fibroblasts, and in each donor the response was approximately equal to the total frequency of CD8 + T cells that produced IFNγ after stimulation with the pp65 peptides ( Table 1 ). In one donor (#9), CD8 + T cells that produced IFNγ after stimulation with AD169-infected fibroblasts were selected by flow cytometry and cloned by limiting dilution. All of the T cell clones recognized autologous AD169-infected but not mock-infected fibroblasts, and >90% lysed autologous LCL infected with vac/pp65 (data not shown). These results demonstrate that stimulation with AD169-infected cells predominantly detects CTL specific for structural virion proteins such as pp65, and a lower frequency of CD8 + CMV-specific CTL than stimulation with RV798-infected fibroblasts.
For (Table 2) . However, only a fraction (17-63%) of the clones from each donor lysed AD169-infected fibroblasts (Table 2) .
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A. Autologous fibroblasts were infected with RV798 for 48 hours or AD169 for 16 hours and used as target cells in a chromium release assay. Aliquots of autologous LCL were infected with each of the vaccinia CMV recombinant viruses for 12 hours. Clones categorized as lysing RV798-infected target cells exhibited >20% lysis of RV798-infected cells and <3% lysis of mock infected cells. Clone categorized as lysing AD169-infected target cells exhibited >10% lysis of AD169-infected cells and <3% lysis of mock-infected cells. Clones were categorized as specific for a CMV antigen expressed by a vaccinia recombinant virus if they exhibited >20% lysis of cells infected with that vaccinia recombinant and <5% lysis of cells infected with all the other vaccinia recombinant viruses. The effector to target cell ratio in all experiments was 10:1 and the data is derived from duplicate experiments with triplicate samples in each assay.
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We next evaluated recognition by the CTL clones of autologous B-LCL infected with vaccinia recombinant viruses encoding CMV IE-1, pp65, gB, and pp150, and B-LCL pulsed with synthetic peptides derived from pp28, pp50, and UL18 21,25,29,36,40 . CTL specific for pp65 were identified in the panels of clones from all 5 donors, and comprised between 13 and 53% of the total number of clones obtained from each donor. CTL specific for pp150 were identified in the panels of clones from 2 donors and comprised 3 -30% of the clones from these donors ( Table 2 ). The pp65 and pp150-specific CTL efficiently lysed both AD169 and RV798-infected autologous fibroblasts ( Figure 3 ).
CTL clones specific for IE-1 were isolated from four donors and comprised between 3
and 28% of the total number of T cell clones analyzed from each donor, whereas CTL clones specific for gB were isolated from 2 donors and represented <5% of the response in each donor ( Table 2 ). The IE-1 and gB-specific CTL failed to lyse AD169-infected fibroblasts demonstrating that a component of the response detected with RV798 infected fibroblasts in some donors was specific for these previously defined CMV antigens ( Figure 3 ). However, a significant proportion (29 to 80%) of the CD8 + CTL clones isolated from all 5 donors was not specific for any CMV antigens encoded by the panel of recombinant vaccinia viruses, and these CTL lysed only RV798 and not AD169 infected target cells (Table 2 and Figure 3) . None of the T cell clones isolated from donors that expressed HLA A2, A3, B27, and B44 in our study lysed autologous LCL pulsed with peptides corresponding to sequences of pp50, pp28, or UL18 epitopes previously shown to stimulate interferon release from PBMC of CMV seropositive donors with these HLA alleles 36 (data not shown). Thus, the repertoire of CMV-specific CTL in normal CMV seropositive individuals with protective immunity includes a large population of CD8 + T lymphocytes specific for novel CMV antigens.
Figure 3
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For personal use only. on . by guest www.bloodjournal.org From antigens, but did not block recognition by pp65-specific CTL (Figure 4b ). These results suggest that proteins encoded by IE genes or by RNA molecules packaged with the virion are targets for these CMV-specific CTL 42 .
The viral antigens presented >8 hours after infection could be encoded by E or L genes, since the onset of viral DNA replication, which defines the L phase, can begin by 12 hours post infection. Target cells that express only IE and E genes were prepared by pretreatment with ganciclovir, which blocks DNA replication, and tested for recognition by the 11 CTL clones that only lysed fibroblasts infected with RV798 for >8 hours. The efficacy of ganciclovir was confirmed by assaying supernatants obtained 48-108 hours after infection from ganciclovir-treated and control RV798-infected cultures by plaque assay 37 . Ganciclovir completely inhibited virus production (data not shown), but did not interfere with recognition by any of the 11 CTL clones (Figure 4c) . Collectively, these data show a significant component of the CD8 + CTL response to CMV is specific for viral antigens encoded by IE or E genes, which are not presented in fibroblasts infected with wild type CMV due to expression of the US proteins. (a) Fifty-eight CTL clones that were specific for undefined CMV antigens were tested for their ability to lyse autologous fibroblasts infected for various durations with RV798. Data are shown for two CTL clones, clone 1-240 ( ) and clone 1-241 ( ), that exhibited a lytic pattern representative of 47 of the 58 clones and for one CTL clone, clone 2-B23 ( ), that exhibited a lytic pattern representative of the remaining 11 clones. A CTL clone specific for IE-1, clone 1-189 ( ), is included as a control.
(b) Presentation of novel CMV antigens by RV798-infected fibroblasts requires de novo gene expression. Forty-seven CTL clones that recognized targets as early as 2 hours after infection with RV798 were tested for their ability to lyse autologous fibroblasts either mock-infected ( ), infected with RV798 for 4 hours ( ), or infected with RV798 for 4 hours in the presence of Actinomycin D ( ) Representative data is shown for three CTL clones (clone 1-102 is pp65-specific; clone 1-240 and 1-241 are specific for unknown CMV antigens).
(c) Eleven CTL clones that only recognized targets infected for longer than 8 hours were tested for their ability for their ability to lyse autologous fibroblasts either mock-infected ( ) or infected with RV798 for 48 hours ( ), or infected with RV798 for 48 hours in the presence of ganciclovir ( ) at 10µM to abrogate L gene expression. Representative data for 3 of 11 CTL clones from three different donors is shown at an E:T of 10:1.
Analysis of HLA restricting alleles and T cell Vβ receptors reveals a diverse
CD8
+ CTL response to CMV.
The class I HLA presenting molecule was determined for 74 of the CD8 + CTL clones obtained from three of the 5 donors by assessing recognition of RV798-infected fibroblasts from unrelated individuals that were matched at only a single class I allele with the donor. In each of these donors, at least 2 of the 4 class I HLA A and B molecules presented CMV antigens to a subset of the T cell clones (Table 3 ). In donors who expressed both HLA A2 and B7 alleles, the frequency of pp65-specific CTL that were restricted by HLA-B7 was higher than the frequency restricted by HLA-A2, consistent with prior work 43 . The Vβ T cell receptor gene family utilized by each of the 74 CD8 + CTL clones was assessed by a multiplex polymerase chain reaction that allowed for the determination of Vβ gene usage in 5 separate reactions 39 . IE-1 and pp65-specific T cell clones were highly restricted in their Vβ gene expression. In contrast, the CTL of unknown CMV antigen specificity employed a number of distinct TCR Vβ receptors (Table 3 ). For example, the 8 CTL clones from donor 1 that recognized undefined CMV antigens presented by HLA B7 expressed a total of 5 different Vβ T cell receptors. This analysis of HLA restricting alleles and T cell receptor diversity likely underestimates the
+ T cell response to CMV since <20% of the total number of CMV-specific T cell clones obtained from each donor were analyzed. These findings indicate that the CMV-specific CTL repertoire is comprised of a large number of individual clones, although this does not necessarily imply an equivalent number of antigen specificities. 
Discussion
Individuals with impaired CD8 + CMV-specific T cell immunity are at increased risk for CMV reactivation and disease pointing to a crucial contribution of this T cell subset for limiting viral infection 3, 8, 9, 11 . The protective role of CD8 + T cells in CMV is surprising because the virus expresses four glycoproteins that profoundly interfere with the presentation of viral antigens in infected fibroblasts in vitro 37 . US3 is expressed rapidly but transiently after infection, and retains class I molecules in the endoplasmic reticulum (ER) 16 . US2 and US11 are expressed in the E phase and cause retrograde translocation of class I molecules from the ER to the cytosol where they are degraded 15, 18 .
Finally, US6 is expressed in the L phase and blocks transporter associated with antigen processing (TAP)-mediated peptide transport into the ER 17, 44 . The sequential expression of the US proteins is thought to allow CMV-infected cells to efficiently evade T cell recognition.
Analysis of the specificity of the CTL response to CMV using APC infected with AD169 CMV or with recombinant vaccinia viruses encoding individual CMV proteins identified only a few viral target antigens that were less affected by the viral US proteins 19, 21, 23, 25, 41 . The virion protein pp65, which is presented by infected cells without de novo viral gene expression, and IE-1, which is abundantly synthesized immediately after infection, were identified as major targets for the CTL response 19, 25 . However, control of persistent CMV infection by a CTL response focused on only a few viral proteins might be tenuous, since the virus could escape immune control by mutation of only a few epitopes.
For personal use only. 32 . In preliminary studies, we found the human CMV-specific CTL clones isolated here able to recognize uninfected DC that were cocultured with allogeneic AD169-infected fibroblasts (T. The discovery of a population of CD8 + CTL specific for as yet undefined CMV antigens has implications for immunotherapy to control CMV in immunodeficient individuals and for vaccination to prevent infection. The adoptive transfer of CD8 + T cells specific primarily for pp65 has safely restored T cell responses to CMV in hematopoietic stem cell transplant recipients 12, 13 . Preliminary studies suggest this approach prevents CMV disease in susceptible patients, but reactivation of virus measured by detection of CMV antigen in neutrophils or by culture may still occur 12 .
This suggests that the immunologic control of CMV exhibited in normal individuals may not be completely restored by adoptive transfer of a limited repertoire of virus-specific CTL.
Immunization of women prior to childbearing could potentially reduce morbidity from congenital CMV infection 51 . Subunit vaccines incorporating only pp65, IE-1, and gB have been developed and elicit both T cell and antibody responses 52, 53 . Studies to identify the viral genes that encode additional CMV antigens recognized by CD8 + CTL
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